Side effects of Silimarina Bawiss in details
Body as a Whole: Enlarged abdomen, asthenia, body odor, chest pain, chills, suicide, fever, generalized edema, fungal infection, malaise, neck pain, neoplasm, rheumatoid arthritis, and sudden death.
Cardiovascular System: Arrhythmia, bypass surgery, cardiac arrest, hyperlipemia, hypertension, migraine, myocardial infarct, myocardial ischemia, occlusion, peripheral vascular disorder, syncope, and tachycardia.
Digestive System: Anorexia, constipation, dry mouth, dysphagia, colitis, fecal incontinence, gastritis, gastroenteritis, gastrointestinal disorder, increased appetite, intestinal obstruction, melena, pancreatitis, tenesmus, and vomiting.
Hematologic-Lymphatic System: Lymphadenopathy.
Infections and Infestations: Viral infection.
Metabolic and Nutritional Disorders: Edema, hyperglycemia, increased ALT, and increased AST.
Musculoskeletal System: Arthralgia, arthritis, myalgia, pathological fracture, and tendon disorder.
Nervous System: Central nervous system neoplasia, depression, dizziness, emotional lability, facial paralysis, insomnia, vasodilatation, and vertigo.
Respiratory System: Asthma, bronchitis, increased cough, dyspnea, epistaxis, laryngitis, pharyngitis, pneumonia, rhinitis, and sinusitis.
Skin: Alopecia, eczema, pruritus, and sweating.
Special Senses: Cataract.
Urogenital System: Cervix disorder, endometrial carcinoma, epididymitis, and impotence.
Silimarina Bawiss contraindications
Hypersensitivity to milk thistle fruits and/or other plants of the compositae, or to any of the excipients of Silimarina Bawiss.
References
- DTP/NCI. "NSC651520: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "[No public or meaningful name is available]: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
- KEGG. "Anatomical Therapeutic Chemical (ATC) classification". http://www.genome.jp/kegg-bin/get_ht... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Silimarina Bawiss are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Silimarina Bawiss. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported side effects
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
